<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3048">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01441843</url>
  </required_header>
  <id_info>
    <org_study_id>NL3253507810</org_study_id>
    <nct_id>NCT01441843</nct_id>
  </id_info>
  <brief_title>Resistance Under the Microscope</brief_title>
  <official_title>Resistance Under the Microscope; a Randomized Placebo Controlled Parallel Group Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether lorazepam, which is used to lower
      preoperative anxiety, also improves postoperative recovery.

      This study data will also be used for further research aiming to identify vulnerable
      patients in the day-case surgery setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since the early 1980s, the investigators have seen a shift towards day-case surgery. Before
      surgery, many patients have negative feelings about the surgical procedure. These anxieties
      have various negative effects. To reduce this resistance preoperative administration of an
      anxiolytic drug is administered, typically a benzodiazepine. The investigators know that
      benzodiazepines are effective in reducing anxiety, but up to now there is nog good
      scientific evidence about the effectiveness of lorazepam on the quality of recovery in
      day-case surgery patients.

      The ultimate goal of our research project is to identify patients who would benefit from
      preoperative benzodiazepine administration and who not. Identification would substantially
      contribute to optimal medical decision making.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Quality of Recovery Score</measure>
    <time_frame>Baseline; first postoperative working day; seventh postoperative day.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Quality of Recovery Score - 40 (QoR-40), a 40-item scale, is used to assess the quality of recovery.
Each item is rated on a five-point Likert scale (1-5), and the QoR-40 score is calculated as the sum of the scores on these items. Minimal possible score = 40, maximal possible score = 200. A higher score indicates a higher level of quality of recovery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>baseline; after surgery but before discharge; 1 week after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>The State-Trait Anxiety Inventory (STAI) is used to assess anxiety. Scores are calculated by summing the scores on the items, and a higher score indicates a higher level of anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>baseline; 1 week after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Multidimensional Fatigue Inventory (MFI) is used to assess the change in fatigue. The MFI is a self-report instrument designed to measure fatigue. Scores are calculated by summing the scores on the items, and a higher score indicates a higher level of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aggression Regulation</measure>
    <time_frame>baseline; 1 week after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>The State-Trait Anger Scale (STAS) is used to assess the aggression regulation. STAS is one of the most used tools for measuring aggression. Scores are calculated by summing the scores on the items, and a higher score indicates a higher level of aggression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive Mood</measure>
    <time_frame>baseline; 1 week after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Hospital Anxiety and Depression Scale (HADS) is used to assess the change in depression. The HADS is a well known international outcome measurement for anxiety and depression. It is often used in the clinical setting. Scores are calculated by summing the scores on the items, and a higher score indicates a higher level of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Somatic Symptoms and Complaints</measure>
    <time_frame>Baseline; first postoperative working day; 1 week after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Medical records are used to assess somatic symptoms and complaints. Next to the medical records, dimensions of the QoR-40 (physical comfort, physical independence and pain) are used to measure somatic symptoms and complaints.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Lorazepam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lorazepam 4mg/4ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0.9% 4ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorazepam</intervention_name>
    <description>Once 1mg &lt;75kg body weight, 1.5mg 75kg and &gt;75kg body weight, IV, before surgery</description>
    <arm_group_label>Lorazepam</arm_group_label>
    <other_name>Temesta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9% (Sodium Chloride)</intervention_name>
    <description>Once 1ml &lt;75kg body weight, 1.5ml 75kg or &gt;75kg body weight, IV, before surgery</description>
    <arm_group_label>NaCl 0.9%</arm_group_label>
    <other_name>NaCl 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients &gt; 18 years admitted to the Day-Case Surgery Department Erasmus MC

        Exclusion Criteria:

          -  insufficient command of the Dutch language

          -  ophthalmology surgery

          -  Extracorporeal Shock Wave Lithotripsy (ESWL)-, Gastrointestinal endoscopic
             intervention, Botox-, Abortion and Pain treatment

          -  Use of psychopharmaceuticals

          -  Contra-indication of lorazepam use
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Klimek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <results_reference>
    <citation>Mijderwijk H, van Beek S, Klimek M, Duivenvoorden HJ, Gr√ºne F, Stolker RJ. Lorazepam does not improve the quality of recovery in day-case surgery patients: a randomised placebo-controlled clinical trial. Eur J Anaesthesiol. 2013 Dec;30(12):743-51. doi: 10.1097/EJA.0b013e328361d395.</citation>
    <PMID>23635914</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 1, 2016</lastchanged_date>
  <firstreceived_date>September 22, 2011</firstreceived_date>
  <firstreceived_results_date>August 29, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Markus Klimek</investigator_full_name>
    <investigator_title>Vice-head of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>quality of life</keyword>
  <keyword>lorazepam</keyword>
  <keyword>anxiety</keyword>
  <keyword>premedication</keyword>
  <keyword>surgery</keyword>
  <keyword>Adult patients</keyword>
  <keyword>Ambulatory Surgical Procedures</keyword>
  <keyword>Postoperative Period</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lorazepam</title>
          <description>Lorazepam 4mg/4ml
Lorazepam : Once 1mg &lt;75kg body weight, 1.5mg 75kg and &gt;75kg body weight, IV, before surgery</description>
        </group>
        <group group_id="P2">
          <title>NaCl 0.9%</title>
          <description>NaCl 0.9% 4ml
NaCl 0.9% (Sodium Chloride) : Once 1ml &lt;75kg body weight, 1.5ml 75kg or &gt;75kg body weight, IV, before surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>In retrospect, two patients in the lorazepam group should not have been included due to an administrative error. Data for these two patients were, therefore, excluded from analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Lorazepam</title>
          <description>Lorazepam 4mg/4ml
Lorazepam : Once 1mg &lt;75kg body weight, 1.5mg 75kg and &gt;75kg body weight, IV, before surgery</description>
        </group>
        <group group_id="B2">
          <title>NaCl 0.9%</title>
          <description>NaCl 0.9% 4ml
NaCl 0.9% (Sodium Chloride) : Once 1ml &lt;75kg body weight, 1.5ml 75kg or &gt;75kg body weight, IV, before surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="198"/>
                <measurement group_id="B2" value="200"/>
                <measurement group_id="B3" value="398"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="190"/>
                <measurement group_id="B2" value="191"/>
                <measurement group_id="B3" value="381"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="39.5" spread="13.7"/>
                <measurement group_id="B2" value="39.3" spread="13.6"/>
                <measurement group_id="B3" value="39.4" spread="13.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="89"/>
                <measurement group_id="B2" value="85"/>
                <measurement group_id="B3" value="174"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="109"/>
                <measurement group_id="B2" value="115"/>
                <measurement group_id="B3" value="224"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Netherlands</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="198"/>
                <measurement group_id="B2" value="200"/>
                <measurement group_id="B3" value="398"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quality of Recovery Score</title>
        <description>The Quality of Recovery Score - 40 (QoR-40), a 40-item scale, is used to assess the quality of recovery.
Each item is rated on a five-point Likert scale (1-5), and the QoR-40 score is calculated as the sum of the scores on these items. Minimal possible score = 40, maximal possible score = 200. A higher score indicates a higher level of quality of recovery.</description>
        <time_frame>Baseline; first postoperative working day; seventh postoperative day.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Lorazepam</title>
            <description>Lorazepam 4mg/4ml
Lorazepam : Once 1mg &lt;75kg body weight, 1.5mg 75kg and &gt;75kg body weight, IV, before surgery</description>
          </group>
          <group group_id="O2">
            <title>NaCl 0.9%</title>
            <description>NaCl 0.9% 4ml
NaCl 0.9% (Sodium Chloride) : Once 1ml &lt;75kg body weight, 1.5ml 75kg or &gt;75kg body weight, IV, before surgery</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="188"/>
                  <measurement group_id="O2" value="195"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Quality of Recovery Score</title>
            <description>The Quality of Recovery Score - 40 (QoR-40), a 40-item scale, is used to assess the quality of recovery.
Each item is rated on a five-point Likert scale (1-5), and the QoR-40 score is calculated as the sum of the scores on these items. Minimal possible score = 40, maximal possible score = 200. A higher score indicates a higher level of quality of recovery.</description>
            <units>scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Seventh postoperative day</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="172.8" spread="21.0"/>
                  <measurement group_id="O2" value="176.3" spread="18.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>First postoperative working day</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="174.5" spread="13.0"/>
                  <measurement group_id="O2" value="176.4" spread="12.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="177.2" spread="17.4"/>
                  <measurement group_id="O2" value="180.4" spread="17.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anxiety</title>
        <description>The State-Trait Anxiety Inventory (STAI) is used to assess anxiety. Scores are calculated by summing the scores on the items, and a higher score indicates a higher level of anxiety.</description>
        <time_frame>baseline; after surgery but before discharge; 1 week after surgery</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue</title>
        <description>The Multidimensional Fatigue Inventory (MFI) is used to assess the change in fatigue. The MFI is a self-report instrument designed to measure fatigue. Scores are calculated by summing the scores on the items, and a higher score indicates a higher level of fatigue.</description>
        <time_frame>baseline; 1 week after surgery</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aggression Regulation</title>
        <description>The State-Trait Anger Scale (STAS) is used to assess the aggression regulation. STAS is one of the most used tools for measuring aggression. Scores are calculated by summing the scores on the items, and a higher score indicates a higher level of aggression</description>
        <time_frame>baseline; 1 week after surgery</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depressive Mood</title>
        <description>The Hospital Anxiety and Depression Scale (HADS) is used to assess the change in depression. The HADS is a well known international outcome measurement for anxiety and depression. It is often used in the clinical setting. Scores are calculated by summing the scores on the items, and a higher score indicates a higher level of depression.</description>
        <time_frame>baseline; 1 week after surgery</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Somatic Symptoms and Complaints</title>
        <description>Medical records are used to assess somatic symptoms and complaints. Next to the medical records, dimensions of the QoR-40 (physical comfort, physical independence and pain) are used to measure somatic symptoms and complaints.</description>
        <time_frame>Baseline; first postoperative working day; 1 week after surgery</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lorazepam</title>
          <description>Lorazepam 4mg/4ml
Lorazepam : Once 1mg &lt;75kg body weight, 1.5mg 75kg and &gt;75kg body weight, IV, before surgery</description>
        </group>
        <group group_id="E2">
          <title>NaCl 0.9%</title>
          <description>NaCl 0.9% 4ml
NaCl 0.9% (Sodium Chloride) : Once 1ml &lt;75kg body weight, 1.5ml 75kg or &gt;75kg body weight, IV, before surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. M. Klimek</name_or_title>
      <organization>Erasmus University Medical Centre</organization>
      <phone>+31107033713</phone>
      <email>m.klimek@erasmusmc.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
